ArticleFrontiers in veterinary science2026
Application of NMR-based metabolomics and machine learning for non-invasive disease screening in dogs.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NMR Metabolomics in Veterinary Medicine: From Biomarker Discovery to Clinical Implementation.Veterinary sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blood-based metabolomics is increasingly recognised as a powerful tool for disease detection in human medicine. However, its application in veterinary science remains limited. Objective: To evaluate the ability of an NMR-based metabolomics platform combined with machine learning to screen dogs for cancer, cardiovascular disease (CVD), and overall health status. Animals: Client-owned dogs were recruited from two sites. Of 156 animals enrolled, 139 remained after exclusions and were used for training and cross-validation of classification models. Methods: Blood samples were obtained from clinically healthy dogs and dogs with a range of diseases. Full blood count was performed, and serum metabolomic and lipoprotein profiling data were generated using NMR spectroscopy. Machine learning classifiers were trained to distinguish healthy from non-healthy dogs, and to further identify cancer and CVD cases. Model performance was evaluated by cross-validation and against null models with permuted class labels. Results: Models showed high discriminative performance for separating healthy from non-healthy animals (ROC AUC 0.916 ± 0.012; accuracy 86.5 ± 3.8%; sensitivity 81.7 ± 6.9%; specificity 87.5 ± 6.0%) and identifying pets with cancer (ROC AUC 0.911 ± 0.008; accuracy 83.5 ± 3.4%; sensitivity 86.5 ± 6.7%; specificity 82.4 ± 6.6%) or CVD (ROC AUC 0.924 ± 0.010; accuracy 90.0 ± 5.8%; sensitivity 85.6 ± 5.1%; specificity 90.6 ± 7.2%) from pets without the disease. Key predictive features included glutamine and creatine concentrations, lymphocyte count and percentage, platelet count and mean platelet volume (MPV), as well as lipoprotein cholesterol levels. Conclusion: This study provides the first evidence that NMR metabolomics combined with machine learning enables accurate, non-invasive, multi-disease screening in dogs, highlighting its potential for translation into routine veterinary practice for diagnosis and health monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.